{"id":7728,"date":"2006-12-17T00:00:00","date_gmt":"2006-12-16T22:00:00","guid":{"rendered":"https:\/\/irb.usi.ch\/uncategorized\/irb-founding-member-of-vaccine-institute-5\/"},"modified":"2006-12-17T00:00:00","modified_gmt":"2006-12-16T22:00:00","slug":"irb-founding-member-of-vaccine-institute-5","status":"publish","type":"post","link":"https:\/\/irb.usi.ch\/it\/news\/irb-founding-member-of-vaccine-institute-5\/","title":{"rendered":"IRB Founding Member of Vaccine Institute"},"content":{"rendered":"

on<\/span> December 17, 2006<\/span><\/p>\n

\n\tA simple phrase in a press release this summer of the Bill and Melinda Gates foundation announcing major funding of HIV research in Switzerland noted: \u201cThe Government of Switzerland has pledged to support the establishment of a vaccine institute in Lausanne that will contribute to the implementation of the Enterprise scienti fic plan.\u201d That ambitious initiative became a reality on December 20th with the official founding of the Swiss Institute for Research in Vaccines, ISVR.<\/p>\n

\n\tDirector Antonio Lanzavecchia The IRB with its powerful immunology and vaccine program is proud to be one of the four founding members of this important and unique institute.The other members are the CHUV, the Ludwig Institute and the EPFL, all based in Luasanne. The ISVR will concentrate first on basic, clinical and translational research in the domain of the three principal infectious diseases;HIV\/AIDS,Tuberculosis (TB) and Malaria. Attention will also be paid to the threat of pandemic flu and the search for effective vaccines against Hepatitis C, Dengue Fever and other infectious diseases.<\/p>\n

\n\t\"Chuv   \"IRB    \"EPFL    \"Ludwig<\/p>\n

\n\tProtective vaccines against a variety of infectious agents represent one of the most significant successes of biomedical research in the 20th century. In spite of this success the most devastating infectious diseases currently facing the world population, HIV\/AIDS,TB and Malaria, are lacking an effective vaccine. The ISVR is dedicated to filling this gap. Recent studies on vaccines against tumors, have fueled optimism in this convergent field of infectious diseases and cancer. More than 20% of cancers are related to infection such as Hepatitis B and C and Human Papiloma. Preventative vaccines have been shown to reduce substantially the incidence of cancer. For this reason the development of a multidisciplinary vaccine program against both infectious agents and cancer will encourage the most effective use of resources.The ISVR will favor scientific and technological exchange between researchers in the domains of oncology and immunology leading to effective pre-clinical and clinical development. The ISVR shares its ambitious goal with many international initiatives of academic, political, social, and industrial nature who seek to reduce the devastating effects of infectious diseases and cancer. The principal objectives of the ISVR are: – To develop a platform of immunology laboratories open to standardization and for the development of new and innovative technologies to evaluate the immune response induced by vaccines in with the aim of rapidly transferring the most effective candidates to pre-clinical and clinical experiments.<\/p>\n